Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Clinical Lung Cancer, 6(16), p. e223-e228

DOI: 10.1016/j.cllc.2015.04.006

Links

Tools

Export citation

Search in Google Scholar

Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

Journal article published in 2015 by Giovenzio Genestreti, Marcello Tiseo, Hirotsugu Kenmotsu, Wakuda Kazushige, Monica Di Battista, Giovanna Cavallo, Federica Carloni, Alberto Bongiovanni ORCID, Marco Angelo Burgio, Claudia Casanova, Giulio Metro, Emanuela Scarpi, Taner Korkmaz, Seber Selcuk, Roopa Kurup and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL) chemotherapy have a poor prognosis and second-line (SL) chemotherapy has limited efficacy. Patients whose disease relapses/progresses > 90 days after FL platinum-based treatment are considered platinum-sensitive and could be rechallenged with a similar regimen. We conducted a multicenter retrospective analysis to evaluate outcomes of SCLC patients rechallenged with platinum/etoposide.